
Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients
Focusing on the unmet medical needs of patients with rare disorders and their families
Our Company
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Latest News
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
Read MoreZynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Read MoreZynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
Read MoreZynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygelâ„¢ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting
Read More